Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Abdominal Radiology
Published in: Abdominal Radiology 2/2007

01-04-2007

Prostate cancer detection: magnetic resonance (MR) spectroscopic imaging

Authors: Joan C. Vilanova, Joaquim Barceló

Published in: Abdominal Radiology | Issue 2/2007

Login to get access

Abstract

Magnetic resonance spectroscopic imaging (MRSI) represents a noninvasive technique to extend the diagnostic evaluation of prostatic cancer, beyond the morphologic information provided by MR imaging throughout the detection of cellular metabolites (choline and citrate). MRSI combined with the anatomical information provided by MRI can improve the assessment cancer location and extent within the prostate, extracapsular spread and cancer aggressiveness; both before and after treatment. We review the performance of MRI with MRSI and the role in the detection, localization, staging and management of the patient pre- and posttherapy for prostate cancer.
Literature
1.
Gilliland FD, Hunt WC, Key CR (1996) Improving survival for patients with prostate cancer diagnosed in the prostate-specific antigen era. Urology 48:67–71PubMedCrossRef
2.
Cooperberg MR, Lubeck DP, Grossfeld GD, et al. (2002) Contemporary trends in imaging test utilization for prostate cancer staging: data from the cancer of the prostate strategic urologic research endeavour. J Urol 168:491–495PubMedCrossRef
3.
Kurhanewicz J, Swanson MG, Nelson SJ, et al. (2002) Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imaging 16:451–463PubMedCrossRef
4.
Rajesh A, Coakley FV (2004) MR imaging and MR spectroscopic imaging of prostate cancer. Magn Reson Imaging Clin North Am 12:557–579CrossRef
5.
Tsuda K, Yu KK, Coakley FV, et al. (1999) Endorectal MR imaging of prostate cancer: role of fat suppresion in the detection of extracapsular detection. J Comput Assist Tomogr 23:74–78PubMedCrossRef
6.
Rouvière O, Raudrant A, Ecochard R et al. (2003) Characterization of timeenhancement curves of benign and malignant prostate tissue at dynamic MR imaging. Eur Radiol 13:931–941PubMed
7.
Prezioso P, Orlacchio A, Giambattista GD, et al. (2003) Enhancement patterns of prostate cancer in dynamic MRI. Eur Radiol 13:925–930
8.
Van Dorsten FA, Van der Graaf M, Engelbrecht MRW, et al. (2004) Combined quantitative dynamic contrast-enhanced MR imaging and 1H MR spectroscopic imaging of human prostate cancer. J Magn Reson Imaging 20:279–287PubMedCrossRef
9.
Engelbrecht M, Huisman HJ, Laheij RJF, et al. (2003) Discrimination of prostate cancer from peripheral zone and central gland tissue using dynamic contrast-enhanced MR imaging. Radiology 229:248–254PubMedCrossRef
10.
Jung JA, Coakley FV, Qayyum A, et al. (2004) Endorectal MR spectroscopic imaging of the prostate:investigation of a standardized evaluation system. Radiology 233:701–708PubMedCrossRef
11.
Kurhanewicz J, Vigneron DB, Hricak H, et al. (1986) Three dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24–0.7 cm3) spatial resolution. Radiology 198:795–805
12.
Kurhanewicz J, Vigneron DB, Males RG, et al. (2000) The prostate: MR imaging and spectroscopy: present and future. Radiol Clin North Am 38:115–138PubMedCrossRef
13.
Qayyum A, Coakley FV, Lu Y, et al. (2004) Effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol 183:1079–1083PubMed
14.
Vilanova JC, Comet J, Capdevila A, et al. (2001) The value of endorectal MR imaging to predict positive biopsies in clinically intermediate-risk prostate cancer patients. Eur Radiol 11:229–235PubMedCrossRef
15.
Cruz M, Tsuda K, Narumi Y, et al. (2002) Characterization of low-intensity lesions in the peripheral zone of prostate on pre-biopsy endorectal coil MR imaging. Eur Radiol 12:357–365PubMedCrossRef
16.
Claus FG, Hricak H, Hattery RR (2004) Pretreatment evaluation of prostate cancer: role of MR imaging and 1H MR spectroscopy. Radiographics 24:S167–S180PubMedCrossRef
17.
Scheidler J, Hedvig Hricak H, Vigneron DB, et al. (1999) Prostate cancer: Localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology 213:473–480PubMed
18.
Kaji Y, Kurhanewicz J, Hricak H, et al. (1998) Localizing prostate cancer in the presence of post-biopsy changes on MR imaging: role of proton MR spectroscopic imaging. Radiology 206:785–790PubMed
19.
Beyersdorff D, Taupitz M, Winkelmann B, et al. (2002) Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. Radiology 224:701–706PubMedCrossRef
20.
Perrotti M, Han KR, Epstein RE, et al. (1999) Prospective evaluation of endorectal magnetic resonance imaging to detect tumor foci in men with prior negative prostatic biopsy: a pilot study. J Urol 162:1314–1317PubMedCrossRef
21.
Comet-batlle J, Vilanova-Busquets JC, Saladie-Roig JM, et al. (2003) Endorectal MRI in the early diagnosis of prostate cancer. Eur Urol 44:201–208PubMedCrossRef
22.
Vilanova JC, Comet J, Barceló AJ, et al. (2004) The value of MR spectroscopic imaging for prostate cancer detection in the peripheral and transitional zone in patients with elevated PSA and negative biopsy (abstr). Radiology (p) 233:270
23.
Zakian KL, Eberhardt S, Hricak H, et al. (2003) Transition zone prostate cancer: metabolic characteristics at 1H spectroscopic imaging-initial results. Radiology 229:241–247PubMedCrossRef
24.
Zakian KL, Sircar K, Hricak H, et al. (2005) Correlation of Proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 234:804–814PubMedCrossRef
25.
Yu KK, Scheidler J, Hricak H (1999) Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 213:481–488PubMed
26.
Wefer AE, Hricak H, Vigneron DB, et al. (2000) Sextant location of prostate cancer : comparison od sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step-section histology. J Urol 164:400–404PubMedCrossRef
27.
Purohit RS, Shinohara K, Meng MV, Carrol PR (2003) Imaging clinically localized prostate cancer. Urol Clin North Am 30:279–293PubMedCrossRef
28.
Huch Boni RA, Boner JA, Debatin JF, et al. (1995) Optimization of prostate carcinoma staging:comparison of imaging and clinical methods. Clin Radiol 50:593–600PubMedCrossRef
29.
Engelbrecht MR, Jager GJ, Laheij RJ, Verbeek AL, Van Lier HJ, Barentsz JO (2002) Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol 12:2294–2302PubMed
30.
Jager GJ, Ruijter ET, van de Kaa CA, et al. (1996) Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. AJR Am J Roentgenol 166:845–852PubMed
31.
Cornoud F, Flam T, Chauveinc L, et al. (2002) Extraprostatic spread of clinically localized prostate cancer: factors predictive of pT3 tumor and of positive endorectal MR imaging. Radiology 224:203–210CrossRef
32.
Wang L, Mullerad M, Chen HN, et al. (2004) Prostate cancer: incremental value of endorectal MR imaging findings for prediction of extracapsular extension. Radiology 232:133–139PubMedCrossRef
33.
Coakley FV, Kurhanewicz J, Lu Y, et al. (2002) Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 223:91–97PubMedCrossRef
34.
Partin AW, Hanks GE, Klein EA, et al. (2002) Prostate-specific antigen as a marker of disease activity in prostate cancer. Oncology 16:1024–1038PubMed
35.
Sella T, Schwartz LH, Swindle PW, et al. (2004) Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 231:379–385PubMedCrossRef
36.
Coakley FV, The HS, Qayyum A, et al. (2004) Endorectal and MR spectroscopic imaging of locally recurrent prostate cancer after external beam radiation theraphy: preliminary experience. Radiology 233:441–448PubMedCrossRef
37.
Mueller-Lisse UG, Vigneron DB, Hricak H, et al. (2001) Localized prostate cancer:effect of hormone deprivation therapy measured by using combined three-dimensional 1H MR spectroscopy and MR imaging: clinicopathologic case-controlled study. Radiology 221:380–390PubMedCrossRef
38.
Vilanova JC, Barceló J (2005) Pelvis masculina: Próstata y testículos. In: Martí Bonmatí L, Vilanova JC (eds). Resonancia Magnética de Cuerpo. Edikamed, Barcelona, pp 149–162
Metadata
Title
Prostate cancer detection: magnetic resonance (MR) spectroscopic imaging
Authors
Joan C. Vilanova
Joaquim Barceló
Publication date
01-04-2007
Publisher
Springer-Verlag
Published in
Abdominal Radiology / Issue 2/2007
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-007-9191-7

Other articles of this Issue 2/2007

Abdominal Radiology 2/2007 Go to the issue

OriginalPaper

Severity prediction in acute pancreatitis: the role of early CT scan

Feature Section, Ultrasonography of the Pancreas

Guest Editors’ introduction

OriginalPaper

Diverticulitis of the small bowel: CT diagnosis

OriginalPaper

Ultrasonography of the pancreas. 5. Interventional procedures

OriginalPaper

Acute adrenal hemorrhage after blunt trauma

OriginalPaper

Ultrasonography of the pancreas. 4. Contrast-enhanced imaging
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits